HLB’s Third FDA CRL for Rivoceranib: Why Phase 3 Efficacy and Manufacturing cGMP Are Separate Questions

원문 링크: WordPress 원문

공개 시장 해설용 글입니다. 투자 조언이 아닙니다.

언어 선택 / Choose a language

KO · 한국어EN · English

Clinical evidence and manufacturing quality must clear separate gates within the same approval review.

HLB’s Third FDA CRL for Rivoceranib: Why Phase 3 Efficacy and Manufacturing cGMP Are Separate Questions

What happened on July 9–10, 2026

On July 9, 2026, local time, Elevar Therapeutics — HLB’s U.S. subsidiary — received a third Complete Response Letter (CRL) from the U.S. FDA for the rivoceranib plus camrelizumab (SHR-1210) combination. HLB disclosed the news the following day, July 10, through Korea’s electronic disclosure system, DART.

What the filing actually establishes is narrow but clear. During a cGMP (current Good Manufacturing Practice) inspection, the FDA identified deficiencies at a manufacturing facility. Satisfactory resolution depends on the FDA determining that the facility has returned to cGMP compliance, and the filing notes that a reinspection may be required. Elevar has said it intends to correct the issues and resubmit.

The filing also states that the deficiencies may not be specific to Elevar’s application alone. What it does not include is equally important: the full CRL text, the identity of the facility, a complete list of observations, a remediation plan, or a confirmed resubmission date.

The one-sentence thesis

Clinical evidence and manufacturing compliance are separate regulatory gates, and neither one, by itself, predicts whether or when approval follows.

Who HLB, Elevar, and Jiangsu Hengrui are

HLB is the Korea-listed company that has led rivoceranib’s development. Elevar Therapeutics is HLB’s U.S. subsidiary and the entity responsible for the New Drug Application (NDA) and the regulatory relationship with the FDA in the United States — it is Elevar, not HLB directly, that received this CRL.

Camrelizumab (SHR-1210) is a PD-1 inhibitor developed by China’s Jiangsu Hengrui Pharma. In October 2023, Elevar and Hengrui announced a global commercialization and licensing agreement covering the camrelizumab-plus-rivoceranib combination for first-line treatment of unresectable hepatocellular carcinoma (HCC). Hengrui is therefore both camrelizumab’s developer and a sponsor tied to the underlying trial program. No public document lays out the precise division of manufacturing responsibility between the parties, and this piece does not assume one.

Three CRLs, three different causes

The three CRLs do not share a single root cause, and compressing them into “the same recurring problem” would misstate the record.

Date DART receipt number Publicly stated core reason

Received 2024-05-17 (filed 2024-05-20) 20240520900509 (1) Rivoceranib approval held over deficiencies involving camrelizumab (2) A BIMO clinical-site inspection could not be completed because of travel restrictions

Received 2025-03-20 20250321900045 FDA would not approve rivoceranib until a regulatory approval action was issued for SHR-1210, because rivoceranib’s safety and effectiveness had been established only in combination with SHR-1210

Received 2026-07-09 (filed 2026-07-10) 20260710900006 Deficiencies identified at a facility during a cGMP inspection; resolution depends on the FDA confirming the facility’s return to cGMP compliance

The 2024 CRL combined camrelizumab-related deficiencies with an incomplete site inspection. The 2025 CRL turned on the absence of a U.S. regulatory action for camrelizumab itself. The 2026 CRL, as publicly described, points to a facility-level cGMP issue as the immediate barrier. These are three distinct problems, and nothing in the current filing supports treating them as one continuous manufacturing story.

Separately, HLB has disclosed that Elevar resubmitted the application on January 23, 2026 (DART receipt 20260126900008), and that the FDA accepted that resubmission. That filing explains the FDA’s Class 1 (roughly two-month) and Class 2 (roughly six-month) resubmission review framework, but it does not indicate — and this article does not predict — how the next resubmission will be classified once one occurs.

What a CRL means under 21 CFR 314.110

Under FDA regulation 21 CFR 314.110, a CRL is formal notice that the agency will not approve an application in its current form. It is neither an approval nor a minor administrative notice. It is also not, by itself, a permanent rejection. An applicant can respond to the deficiencies and resubmit, and the FDA reviews that response on its own terms. Describing this CRL as proof that the Phase 3 trial “failed,” or as a permanent rejection, therefore misstates what the regulatory action establishes.

CARES-310 efficacy: what the trial showed

The clinical foundation for rivoceranib plus camrelizumab is CARES-310, a randomized, open-label, international Phase 3 trial conducted at 95 sites across 13 countries and regions, enrolling 543 patients. The final analysis, published in Lancet Oncology in 2025 with a data cutoff of June 14, 2023, reported the following:

• Median overall survival (OS): 23.8 months with the combination versus 15.2 months with sorafenib. Hazard ratio (HR) 0.64 (95% CI 0.52–0.79), one-sided p

Confirmed Not public

FDA identified facility deficiencies during a cGMP inspection The specific content of the deficiencies

Resolution depends on FDA confirming the facility’s return to cGMP compliance The facility’s identity and location

A reinspection may be required Any reinspection schedule or confirmed resubmission date

The deficiencies may not be specific to Elevar’s application alone The precise scope of how the deficiencies affect other applications

Elevar has stated an intent to correct the issues and resubmit An expected remediation completion date, or the FDA classification (Class 1/2) of any future resubmission

Notably absent from either column is any public statement, in either direction, about whether the FDA separately raised — or ruled out — clinical efficacy or safety concerns. The current filing neither confirms nor excludes that question.

What has to happen next

The necessary elements are visible, but their sequence and timing are not fully fixed in the public record. Elevar and the relevant facility must assemble an adequate remediation response. The FDA can then decide whether reinspection is needed, but public information does not establish whether any reinspection would occur before a new review or during it. If Elevar submits a complete response, the FDA will accept and classify the resubmission as Class 1 (roughly a two-month review) or Class 2 (roughly six months). This article does not estimate when reinspection, resubmission, or classification will occur.

Competitive context, stated cautiously

Several combination regimens are already approved and in use for first-line HCC treatment in the United States, and it is fair to note, in general terms, that repeated approval delays can be a competitive disadvantage in terms of market positioning. That observation stops there. It is not a comparison of efficacy across trials, and it does not attempt to rank this combination against other approved regimens using numbers drawn from different studies with different designs and populations. That kind of cross-trial ranking would overstate what the data can support, and it is outside the scope of this piece.

A note on medical information

This article is not medical advice. Decisions about hepatocellular carcinoma treatment should be made in consultation with a treating physician.

Approval timing cannot be inferred before remediation, possible reinspection, resubmission acceptance, and review classification are known.

A note on investment information

This article is not investment advice. It does not include buy or sell views, price targets, or any probabilistic assessment of approval, and it should not be used for those purposes.

References

• HLB July 2026 CRL disclosure (DART)

• HLB March 2025 CRL disclosure (DART)

• HLB May 2024 CRL disclosure (DART)

• HLB January 2026 resubmission disclosure (DART)

• Elevar 2024 resubmission announcement

• Elevar 2026 FDA acceptance of resubmission

• Elevar–Jiangsu Hengrui commercialization license announcement

• CARES-310 final analysis, Lancet Oncology

• CARES-310 primary report

• ClinicalTrials.gov NCT03764293

• 21 CFR 314.110

• FDA MAPP 6020.4, resubmission classification

• FDA drug manufacturing inspections

• Yonhap, 2026-07-10

• EDaily Pharm, 2026-07-10